Neumora Therapeutics (NMRA) News Today $0.72 0.00 (-0.18%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.70 -0.01 (-2.05%) As of 04:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmMay 27 at 9:40 PM | globenewswire.comNeumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug developmentMay 24, 2025 | uk.investing.comSoftbank Group CORP. Has $69.34 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Softbank Group CORP. decreased its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 13.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 6,541,190 shares of the company's stock after selling 1,005,726 shares during thMay 18, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of NMRA Q2 EarningsNeumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities research analysts at HC Wainwright decreased their Q2 2025 EPS estimates for Neumora Therapeutics in a research report issued on Tuesday, May 13th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.44) per shMay 17, 2025 | marketbeat.comQ2 EPS Forecast for Neumora Therapeutics Raised by AnalystNeumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Stock analysts at William Blair upped their Q2 2025 EPS estimates for shares of Neumora Therapeutics in a report issued on Tuesday, May 13th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($0May 17, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD trimmed its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 94.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 32,548 shares of the company's stock afteMay 17, 2025 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)Needham & Company LLC reissued a "buy" rating and issued a $5.00 target price on shares of Neumora Therapeutics in a research note on Tuesday.May 15, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Holdings Lessened by Orbimed Advisors LLCOrbimed Advisors LLC lessened its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 46.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 804,996 shares of the company's stock after selling 695,004 shares during the period. OrbimedMay 15, 2025 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Misses Expectations By $0.02 EPSNeumora Therapeutics (NASDAQ:NMRA - Get Free Report) issued its earnings results on Monday. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.02).May 14, 2025 | marketbeat.comKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmMay 14, 2025 | prnewswire.comNeumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finanznachrichten.deNeumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...May 13, 2025 | finance.yahoo.comNeumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comNeumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comWill Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?May 11, 2025 | finance.yahoo.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by AnalystsShares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have received a consensus rating of "Hold" from the nine analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold ratinMay 9, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Increases Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Schonfeld Strategic Advisors LLC boosted its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 273.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 521,013 shares of the company's stoMay 5, 2025 | marketbeat.comNeumora Therapeutics (NMRA) Expected to Announce Quarterly Earnings on TuesdayNeumora Therapeutics (NASDAQ:NMRA) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-neumora-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comNeumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025April 28, 2025 | globenewswire.comCapital International Investors Raises Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Capital International Investors boosted its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 692.1% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 3,700,359 shares of the company's stock after buying an additional 3,233,179 shares dApril 23, 2025 | marketbeat.comKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmApril 16, 2025 | investing.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Hold" by AnalystsNeumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has been assigned a consensus recommendation of "Hold" from the nine analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and threApril 14, 2025 | marketbeat.comNeumora Therapeutics' (NMRA) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a research note on Thursday.April 12, 2025 | marketbeat.comNMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 7, 2025 | globenewswire.comNeumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.April 7, 2025 | globenewswire.comNMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 7, 2025 | businesswire.comNeumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law ...April 7, 2025 | gurufocus.comNeumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRAApril 7, 2025 | prnewswire.comNMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRAApril 6, 2025 | globenewswire.comLevi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming DeadlineApril 6, 2025 | markets.businessinsider.comNMRA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action LawsuitApril 6, 2025 | globenewswire.comFaruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRAApril 6, 2025 | globenewswire.comNMRA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action LawsuitApril 5, 2025 | prnewswire.comNMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The FirmApril 4, 2025 | prnewswire.comNeumora Therapeutics' (NMRA) "Underperform" Rating Reaffirmed at Bank of AmericaBank of America reaffirmed an "underperform" rating and set a $1.00 price objective (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday.April 4, 2025 | marketbeat.comLevi & Korsinsky Reminds Neumora Therapeutics, Inc. ...April 4, 2025 | gurufocus.comLevi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRAApril 4, 2025 | prnewswire.comNMRA Investors Have Opportunity to Lead Neumora Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLPApril 3, 2025 | prnewswire.comNeumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your ...April 3, 2025 | gurufocus.comNeumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.April 3, 2025 | globenewswire.comNMRA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRAApril 3, 2025 | globenewswire.comShareholders of Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – NMRAApril 3, 2025 | globenewswire.comShareholders of Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRAApril 3, 2025 | prnewswire.comB of A Securities Downgrades Neumora Therapeutics (NMRA)April 3, 2025 | msn.comNMRA Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action LawsuitApril 2, 2025 | globenewswire.comNMRA DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Neumora Therapeutics, Inc. Securities Fraud Class Action LawsuitApril 2, 2025 | theglobeandmail.comNMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 2, 2025 | globenewswire.comNMRA Investors Have Final Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 2, 2025 | prnewswire.comNeumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression StudyApril 2, 2025 | tipranks.comNMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineApril 1, 2025 | globenewswire.com Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address NMRA Media Mentions By Week NMRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NMRA News Sentiment▼0.680.87▲Average Medical News Sentiment NMRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NMRA Articles This Week▼38▲NMRA Articles Average Week Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PureTech Health News Today SIGA Technologies News Today Atai Life Sciences News Today Oruka Therapeutics News Today MeiraGTx News Today Autolus Therapeutics News Today Septerna News Today Ginkgo Bioworks News Today Sage Therapeutics News Today MBX Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NMRA) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NMRA Stock Free NMRA Stock Alerts